Jamie Smith
Media Relations
Email: [email protected]
Phone: +46 723 757507
Filippa Stenberg joins Mölnlycke Board of Directors
Gothenburg, Sweden, 4 June 2025.
Mölnlycke is pleased to announce the election of Filippa Stenberg as a deputy board member to its Board of Directors, as of 22 May 2025. Filippa brings over a decade of experience in active ownership with a focus on healthcare investments. She currently serves as a Managing Director of Patricia Industries, part of Investor AB, where she has been instrumental in driving value creation in several globally leading companies.
“We are delighted to welcome Filippa to the Mölnlycke Board,” said Karl-Henrik Sundström, Chairman of the Board. “Her energy, expertise and experience, as well as her strategic vision, will be a tremendous asset to Mölnlycke as we continue to advance our growth journey.”
“I am honoured to join the Mölnlycke Board at such a pivotal time,” added Filippa. “The company has been experiencing strong growth in a healthcare landscape that is continuously evolving. I very much look forward to working with the team to help fulfil the company’s purpose to revolutionise care for people and planet.”
Filippa Stenberg was born in 1985 and is a Swedish citizen. She has been a board member of Swedish Orphan Biovitrum AB since 2021 and recently joined the board of Affibody Medical AB. She has worked as an investment professional at Investor AB since 2012, Chief Strategy Officer at Atlas Antibodies and analyst at Swedbank. She holds an MSc in Business and Economics from the Stockholm School of Economics.
For more information, please contact:
Latest news
Read all news-
EUR bond issue and tender announcement
Mölnlycke intends to issue a new 10-year EUR bond and launches a tender offer for the outstanding EUR 500m bond due February 2025.
-
Mölnlycke Health Care expands investment in Tamer Mölnlycke Care joint venture
Mölnlycke Health Care, a world leading MedTech company, has expanded its commitment to operations in the Middle East by extending its stake from 33.3% to 60% to become majority shareholder in Tamer Mölnlycke Care - a joint venture with Tamer Group, the market leader in healthcare distribution in the Kingdom of Saudi Arabia.
-
Mölnlycke Health Care agrees to acquire leading wound cleansing manufacturer to consolidate its position as global leader in wound care
Mölnlycke signed an agreement to acquire P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturizing.
-
Mölnlycke signs a EUR 350 million revolving credit facility
On 28 April 2023, Mölnlycke entered into a new EUR 350 million multicurrency revolving credit facility. The facility has a tenor of five years with two one-year extension options and will be used as a backup for general corporate purposes. The facility is a refinancing of the existing and undrawn revolving credit facility signed in 2017.
-
Mölnlycke integrated Annual Report 2023
Today we are delighted to announce the launch of the Mölnlycke integrated Annual Report 2023. Our dedication to revolutionising care for people and planet contributed to a very successful year with record high annual net sales of EUR 1,924 million and substantial improvements in profitability. We continue to report our sustainability achievements in accordance with the Global Reporting Initiative (GRI) standards.
-
In 2023 Mölnlycke was awarded a gold medal for Sustainability by EcoVadis
The world’s largest and most trusted provider of business sustainability ratings - EcoVadis, has awarded Mölnlycke a gold medal for our focus on sustainability. They have ranked us in the top 3% of companies worldwide.
-
Mölnlycke announces new partnership with burn survivors organisation Phoenix Society
Mölnlycke Health Care is pleased to announce our partnership with Phoenix Society for Burn Survivors.
-
Mölnlycke Health Care secures USD 400 Million in financing from SEK to support global expansion strategy
Stockholm/Gothenburg – 24 June, 2025. Mölnlycke Health Care and The Swedish Export Credit Corporation (SEK) have signed a USD 400 million financing agreement to support the healthcare company’s continued global growth and development.
-
Mölnlycke Health Care’s long-term target to reach net zero emissions validated by Science Based Targets initiative
Gothenburg, Sweden. 13 May, 2025. Mölnlycke’s long-term net zero greenhouse gas (GHG) emission reduction targets have been validated by the Science Based Targets initiative (SBTi), following prior validation of the company’s near-term GHG emission reduction targets.